Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SANOFI : PRESS RELEASE : Former Research Chemist At Global Pharmaceutical Company Sentenced To 18 Months In Prison For Theft Of Trade Secrets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 07:17pm CEST

United States Attorney

District of New Jersey

FOR IMMEDIATE RELEASE CONTACT: Rebekah Carmichael

May 7, 2012 Office of Public Affairs

www.justice.gov/usao/nj (973) 645-2888

FORMER RESEARCH CHEMIST AT GLOBAL PHARMACEUTICAL COMPANY

SENTENCED TO 18 MONTHS IN PRISON FOR THEFT OF TRADE SECRETS

TRENTON, N.J. - A former research chemist with global pharmaceutical company

sanofi-aventis ("sanofi") was sentenced today to 18 months in prison for stealing sanofi's trade

secrets and making them available for sale through Abby Pharmatech, Inc. ("Abby"), the U.S.

subsidiary of a Chinese chemicals company, U.S. Attorney Paul J. Fishman announced.

Yuan Li, 30, of Somerset, N.J., a Chinese national, previously pleaded guilty to an

Information charging her with one count of theft of trade secrets. Li entered her guilty plea

before U.S. District Judge Joel A. Pisano, who also imposed the sentence today in Trenton

federal court.

According to documents filed in this case and statements made in court:

Sanofi is a global healthcare company with U.S. headquarters in Bridgewater, N.J.

Among other things, sanofi is engaged in the development, manufacture and marketing of

healthcare products including the prescription drugs Allegra, Plavix, Copaxone and Ambien.

Li worked as a research scientist at sanofi's Bridgewater headquarters from October 2006

through June 2011, where she directly assisted in the development of a number of compounds

that sanofi viewed as potential building blocks for future drugs. These compounds were sanofi's

trade secrets and had not been disclosed outside of sanofi in any manner, including by means of a

patent application.

While employed at sanofi, Li was also a 50 percent partner in Abby, which is engaged in

the sale and distribution of pharmaceuticals.

Li admitted that between January 2010 and June 2011, she accessed an internal sanofi

database and downloaded information related to a number of sanofi compounds, including their

chemical structures, onto her sanofi-issued laptop computer. She also admitted she then

transferred the information to her personal home computer by sending it to her personal e-mail

address or via a USB thumb drive.

Li acknowledged that she made the stolen compounds available for sale on Abby's

website.

In addition to the prison term, Judge Pisano sentenced Li to serve two years of supervised

release and ordered her to pay $131,000 in restitution.

U.S. Attorney Fishman credited special agents of the FBI, under the direction of Special

Agent in Charge Michael B. Ward, with the investigation.

The government is represented by Assistant U.S. Attorney Gurbir S. Grewal of the

Computer Hacking and Intellectual Property Section of the U.S. Attorney's Office Economic

Crimes Unit in Newark.

12-159 ###

Defense counsel: Paul Brickfield Esq., River Edge, N.J.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04/29 ZEALAND PHARMA AKTIESELSKABET : reports Q1 2017 royalty revenue
04/29 SANOFI : Evidation Health Secures Financing From Sanofi-Genzyme BioVentures to F..
04/28 SANOFI SA (NYSE : SNY) reported earnings of $1.42 per share beating Walls Street..
04/28 SANOFI : beats 1Q profit forecasts
04/28 SANOFI : and Regeneron receive CHMP positive opinion for rheumatoid arthritis tr..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/28 SANOFI : Delivers Robust Q1 2017 Financial Results
04/28 SANOFI : and Regeneron Announce Kevzara® (sarilumab) Biologics License Applicati..
04/28 SANOFI : Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Ap..
More news
Sector news : Pharmaceuticals - NEC
03:15pDJPFIZER : Drug Makers Take Page From Hollywood to Spread the Risk
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 SNIPPETS ROUNDUP : Sanofi Diabetes Disappointment, And Amgen Pullback Signals CG..
04/28 Sanofi SA (SNY) CEO Olivier Brandicourt on Q1 2017 Results - Earnings Call Tr..
04/28 Sanofi 2017 Q1 - Results - Earnings Call Slides
04/28 FDA accepts sarilumab BLA resubmission, action date May 22
04/28 Sanofi Q1 top line up 11%; earnings up 425% on sale of animal heath unit; sha..
Advertisement
Financials (€)
Sales 2017 36 455 M
EBIT 2017 9 316 M
Net income 2017 6 663 M
Debt 2017 4 680 M
Yield 2017 3,51%
P/E ratio 2017 16,71
P/E ratio 2018 17,91
EV / Sales 2017 3,20x
EV / Sales 2018 3,06x
Capitalization 111 902 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 83,5 €
Spread / Average Target -3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI12.63%121 897
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.31%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results